action

Rosuvastatin calcium (ZD4522) , a selective and competitive inhibitor of hepatic hydroxymethyl-glutaryl coenzyme A (HMG-CoA) reductase, has antilipidemic activity.

Bekanamycin (Kanamycin B) is an aminoglycoside antibiotic extracted from Streptomyces kanamyceticus, which inhibits a range of Gram-positive and Gram-negative bacteria.

Disopyramide (Triombrin) is a class I anti-arrhythmic agent (one that interferes directly with the depolarization of the cardiac membrane and thus serves as a membrane-stabilizing agent) with a depressant action on the heart similar to that of guanidine. It also possesses some anticholinergic and local anesthetic properties.

Rosuvastatin (ZD4522) is an inhibitor of HMG-CoA reductase (HMGCR) (IC50=11 nM), selective and competitive. Rosuvastatin has hypolipidemic and antiatherosclerotic effects.

Harmane (Loturine) is a bio-active β-Carboline and monoamine oxidase inhibitor found in coffee and tobacco smoke.

p53 and MDM2 proteins-interaction-inhibitor dihydrochloride is a compound that inhibits the interaction between p53 and MDM2 proteins.

The racemic p53 and MDM2 proteins-interaction-inhibitor is an inhibitor of the interaction between p53 and MDM2 proteins.

ERK-MYD88 Interaction Inhibitor 1, an agent that disrupts the interaction between ERK and MYD88, has demonstrated the ability to trigger an HRI-mediated integrated stress response (ISR) that specifically promotes immunogenic cell apoptosis (apoptosis) in cancer cells. Additionally, in models using Lewis lung cancer mice, this compound has been shown to stimulate anti-tumor T cell responses, thereby exhibiting significant anti-tumor activity.

PRL3-CNNM4 interaction-IN-1 (Compound C28d52) is an inhibitor of the PRL3-CNNM4 interaction that also suppresses CNNM inhibition mediated by PRL. This compound exhibits favorable pharmacokinetic and drug metabolism properties.

RGS2–Galpha-q interaction-IN-1 (Compound AJ-3) is an inhibitor of the RGS2-Galpha-q interaction. It inhibits the growth of cancer cell lines that express RGS2 and has anti-cell migration properties.

Row174336 (compound 29) serves as an efficient inhibitor of the Hsp110-STAT3 interaction, exhibiting antiproliferative activity in the HPAEC cell line with an IC50 of 22.67 μM.

Hsp110-STAT3 interaction-IN-2 (compound 10b) is an inhibitor of the Hsp110-STAT3 interaction. It is utilized in research related to pulmonary arterial hypertension (PAH).

HA-CD44 interaction inhibitor 1 is an anti-tumor agent, which is a hyaluronic acid inhibitor targeting CD44. HA-CD44 interaction inhibitor 1 can inhibit MDA-MB-231 cells with an EC50 of 1.77 μM.

HA-CD44 interaction inhibitor 3 (compound 5d) is an inhibitor of the Hyaluronic acid (HA)-CD44 interaction. It has inhibitory effects on MDA-MB-231 (CD44++) cells and MCF-7 (CD44--) cells with EC50 values of 4.24 μM and 14.74 μM, respectively. HA-CD44 interaction inhibitor 3 is applicable to cancer research.

RNAP-σ interaction inhibitor-2 (compound 7d) is an inhibitor targeting the interaction between RNA polymerase and the sigma factor. It demonstrates inhibitory activity against S. aureus with a minimum inhibitory concentration (MIC) of 2 µg/mL.

CYCS-INPP4A interaction-IN-1 (10A3) disrupts the CYCS-INPP4A interaction complex and enhances ferroptosis-mediated tumor suppression.

RNAP-σ interaction inhibitor-1 (compound 5d) acts as an inhibitor of the interaction between RNA polymerase and the sigma factor. It exhibits activity against Streptococci with a minimum inhibitory concentration (MIC) ranging from 1-2 µg/mL.

TRF1-TIN2 interaction-IN-1 (Compound 40) is an inhibitor of the TRF1-TIN2 interaction. It binds to the TRFH domain of TRF1 (KD= 29 μM) and competitively inhibits the binding of the TIN2 peptide (IC50= 67 μM). By occupying a hotspot at the TRF1-TIN2 interface, TRF1-TIN2 interaction-IN-1 disrupts the interaction between TRF1 and TIN2. This compound can remove TRF1 from the shelterin complex, making it useful for research on shelterin-related cancers.

NusB-NusE interaction inhibitor-1 is a modulator of the NusB-NusE interaction.

B7/CD28 interaction inhibitor 1 (CTLA-4 inhibitor) is a potent CTLA-4 inhibitor.

12-oxo-N-[1-(propan-2-yl)piperidin-4-yl]-6H,7H,8H,9H,10H,12H-azepino[2,1-b]quinazoline-3-carboxamide available as a molecular structural unit, it is used in the synthesis of various compounds.

SORT-PGRN Interaction Inhibitor 3 (Compound 13), with an IC50 value of 0.17 μM, acts as an inhibitor of the SORT-PGRN interaction, and is utilized in the study of neurodegenerative diseases [1].

Beclin1-ATG14L Interaction Inhibitor 1 (COM 19) is a selective inhibitor targeting the specific interaction between Beclin1 and ATG14L. It impedes the formation of complex I in the lipid kinase VPS34, thus inhibiting autophagy, while leaving complex II intact, which relies on the Beclin 1-UVRAG interaction for its integrity and is essential for vesicle transport [1].

SAAP Fraction 3, an antimicrobial peptide, exhibits activity against P. haemolytica in Zn-saline buffer [1].